NKX3-2

Across TCGA pan-cancer cohorts, NKX3-2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of NKX3-2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where NKX3-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NKX3-2 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

LUAD, BLCA, and HNSC are the cancer types where NKX3-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NKX3-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	+0.650	<.001	11	view →
BLCA	All	All	+0.635	<.001	9	view →
HNSC	All	All	+0.592	<.001	9	view →
LUSC	All	II,III,IV	+1.020	<.001	6	view →
BRCA	All	III,IV	+0.927	<.001	6	view →
COAD	All	All	−0.717	.002	6	view →
KIRP	All	III,IV	+0.422	.006	5	view →
LIHC	All	All	+0.179	<.001	5	view →
READ	All	All	−1.413	.011	4	view →
STAD	Female	All	−2.178	.010	3	view →
KIRC	Male	II,III,IV	+0.065	.021	3	view →
CHOL	Female	All	+0.340	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

NKX3-2–LUAD

Open the LUAD breakdown →